262 related articles for article (PubMed ID: 17145573)
1. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Wood JC; Otto-Duessel M; Gonzalez I; Aguilar MI; Shimada H; Nick H; Nelson M; Moats R
Transl Res; 2006 Nov; 148(5):272-80. PubMed ID: 17145573
[TBL] [Abstract][Full Text] [Related]
2. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.
Otto-Duessel M; Aguilar M; Nick H; Moats R; Wood JC
Exp Hematol; 2007 Jul; 35(7):1069-73. PubMed ID: 17588475
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
[TBL] [Abstract][Full Text] [Related]
4. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Kolnagou A; Kontoghiorghes GJ
Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
6. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Kontoghiorghes GJ
Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
[TBL] [Abstract][Full Text] [Related]
7. Treating iron overload: the state of the art.
Hershko C
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S2-4. PubMed ID: 15846582
[No Abstract] [Full Text] [Related]
8. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
[TBL] [Abstract][Full Text] [Related]
10. Monitoring and treatment of iron overload: state of the art and new approaches.
Porter JB
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S14-8. PubMed ID: 15846580
[No Abstract] [Full Text] [Related]
11. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Otto-Duessel M; Brewer C; Gonzalez I; Nick H; Wood JC
Acta Haematol; 2008; 120(2):123-8. PubMed ID: 19018129
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of deferasirox in preventing cardiovascular complications in the iron-overloaded gerbil.
Al-Rousan RM; Manzoor K; Paturi S; Arvapalli RK; Laurino JP; Darnon L; Walker EM; Blough ER
J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):117-25. PubMed ID: 21593444
[TBL] [Abstract][Full Text] [Related]
15. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.
Hershko C; Link G; Konijn AM; Huerta M; Rosenmann E; Reinus C
J Lab Clin Med; 2002 Jan; 139(1):50-8. PubMed ID: 11873245
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
17. Current status of iron overload and chelation with deferasirox.
Choudhry VP; Naithani R
Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
20. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
